董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Wilhelmus Groenhuysen | 男 | Director | 65 | 9.89万美元 | 未持股 | 2023-04-18 |
| Ramy A. Mahmoud | 男 | Chief Executive Officer and Director | 58 | 114.00万美元 | 未持股 | 2023-04-18 |
| R. John Fletcher | 男 | Director | 77 | 12.83万美元 | 未持股 | 2023-04-18 |
| Eric Bednarski | 男 | Director | 52 | 8.53万美元 | 未持股 | 2023-04-18 |
| Eric Bednarski | -- | Director | 51 | 未披露 | 未持股 | 2023-04-18 |
| Kyle Dempsey | 男 | Director | 34 | 8.89万美元 | 未持股 | 2023-04-18 |
| R. John Fletcher | 男 | Director | 77 | 未披露 | 未持股 | 2023-04-18 |
| Sandra L. Helton | 女 | Director | 73 | 未披露 | 未持股 | 2023-04-18 |
| Tomas J. Heyman | 男 | Director | 67 | 8.64万美元 | 未持股 | 2023-04-18 |
| Catherine Owen | 女 | Director | 52 | 9.64万美元 | 未持股 | 2023-04-18 |
| Sandra L. Helton | 女 | Director | 73 | 10.14万美元 | 未持股 | 2023-04-18 |
| Joseph C. Scodari | 男 | Chairman of the Board | 70 | 13.33万美元 | 未持股 | 2023-04-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ramy A. Mahmoud | 男 | Chief Executive Officer and Director | 58 | 114.00万美元 | 未持股 | 2023-04-18 |
| Anthony J. Krick | 男 | Vice President and Chief Accounting Officer | 42 | 未披露 | 未持股 | 2023-04-18 |
| Paul Spence | 男 | Chief Commercial Officer | 55 | 未披露 | 未持股 | 2023-04-18 |
| Michael F. Marino | 男 | Chief Legal Officer and Corporate Secretary | 47 | 99.67万美元 | 未持股 | 2023-04-18 |
董事简历
中英对照 | 中文 | 英文- Wilhelmus Groenhuysen
-
Wilhelmus Groenhuysen， 2012年以来，他一直是Optinose, Inc.的首席财务官。从2007年到2011年，他曾任职Cephalon公司，最终担任执行副总裁兼首席财务官，在那里他负责全球金融、商业运作和风险管理。从1987年到2007年，他曾任职Philips Group公司，担任欧洲、亚洲和美国多种职务，最近于2002年被提拔为Philips Electronics North America Corporation的首席财务官和高级副总裁。他持有VU University Amsterdam的商业经济学硕士学位，以及VU University Amsterdam的注册公共总会计师。
Wilhelmus Groenhuysen,has served as a director of Optinose, Inc. since October 2017. Mr. Groenhuysen served as Chief Financial Officer of NovoCure Limited (NovoCure) from 2012 until August 31, 2020, and has served as NovoCure's Chief Operating Officer since September 1, 2020. At NovoCure, Mr. Groenhuysen has global responsibility for supply chain, patient experience, information technology, quality, business development and strategy. From 2007 to 2011, Mr. Groenhuysen worked for Cephalon, Inc., a U.S. biopharmaceutical company, last serving as Executive Vice President and Chief Financial Officer, where he had responsibility for worldwide finance, commercial operations and risk management. Prior to joining Cephalon in 2007, Mr. Groenhuysen spent twenty years with Philips Electronics serving various assignments in Europe, Asia and the United States, the latest of which started in 2002 when he was promoted to Chief Financial Officer and Senior Vice President of Philips Electronics North America Corporation. Mr. Groenhuysen holds a Master's Degree in Business Economics from VU University Amsterdam and graduated as a Registered Public Controller at VU University Amsterdam. - Wilhelmus Groenhuysen， 2012年以来，他一直是Optinose, Inc.的首席财务官。从2007年到2011年，他曾任职Cephalon公司，最终担任执行副总裁兼首席财务官，在那里他负责全球金融、商业运作和风险管理。从1987年到2007年，他曾任职Philips Group公司，担任欧洲、亚洲和美国多种职务，最近于2002年被提拔为Philips Electronics North America Corporation的首席财务官和高级副总裁。他持有VU University Amsterdam的商业经济学硕士学位，以及VU University Amsterdam的注册公共总会计师。
- Wilhelmus Groenhuysen,has served as a director of Optinose, Inc. since October 2017. Mr. Groenhuysen served as Chief Financial Officer of NovoCure Limited (NovoCure) from 2012 until August 31, 2020, and has served as NovoCure's Chief Operating Officer since September 1, 2020. At NovoCure, Mr. Groenhuysen has global responsibility for supply chain, patient experience, information technology, quality, business development and strategy. From 2007 to 2011, Mr. Groenhuysen worked for Cephalon, Inc., a U.S. biopharmaceutical company, last serving as Executive Vice President and Chief Financial Officer, where he had responsibility for worldwide finance, commercial operations and risk management. Prior to joining Cephalon in 2007, Mr. Groenhuysen spent twenty years with Philips Electronics serving various assignments in Europe, Asia and the United States, the latest of which started in 2002 when he was promoted to Chief Financial Officer and Senior Vice President of Philips Electronics North America Corporation. Mr. Groenhuysen holds a Master's Degree in Business Economics from VU University Amsterdam and graduated as a Registered Public Controller at VU University Amsterdam.
- Ramy A. Mahmoud
-
RamyA.Mahmoud，M.D.，M.P.H.自2010年以来一直担任我们的总裁兼首席运营官。在加入我们之前，马哈茂德博士在强生公司工作了14年，在那里他担任首席医疗官和Ethicon集团公司全球管理委员会成员。在强生公司任职期间，他还在制药行业担任高级职务。Mahmoud博士在美国陆军（U.S.Army）服役10年，在陆军预备役部队（Army Reserves）再服役10年，达到中校军衔。在服兵役期间，Mahmoud博士担任多个病人护理、研究和学术职位，最终担任Walter Reed Army Institute of Research流行病学系主任。他发表了50多篇同行评议论文和教科书章节，并担任多个期刊和教科书的科学评审员。Mahmoud博士在哈佛大学公共卫生学院获得梦百合管理和政策硕士学位，在迈阿密大学获得医学博士学位。
Ramy A. Mahmoud,has served as Optinose, Inc. Chief Executive Officer and as a member of Optinose, Inc. Board of Directors since January 2023. Prior to being appointed Chief Executive Officer, Dr. Mahmoud served as Optinose, Inc. President and Chief Operating Officer since 2010. Prior to joining Optinose, Inc. , Dr. Mahmoud spent 14 years at Johnson & Johnson, where he most recently served as Chief Medical Officer and a member of the Global Management Board of the Ethicon group of companies. During his tenure at Johnson & Johnson, he also held senior roles in the pharmaceutical sector. Dr. Mahmoud served for 10 years on active duty in the U.S. Army and an additional 10 years in the Army Reserves, achieving the rank of Lieutenant Colonel. During his military service, Dr. Mahmoud held various patient care, research, and academic positions, culminating in his position as the head of the Department of Epidemiology at the Walter Reed Army Institute of Research. He has published more than 80 peer-reviewed papers and textbook chapters, and has served as a scientific reviewer for a number of journals and textbooks. Dr. Mahmoud earned a Master of Healthcare Management and Policy degree from the Harvard School of Public Health and an M.D. from the University of Miami. He has earned board certification in both Public Health/Preventive Medicine and in Internal Medicine. - RamyA.Mahmoud，M.D.，M.P.H.自2010年以来一直担任我们的总裁兼首席运营官。在加入我们之前，马哈茂德博士在强生公司工作了14年，在那里他担任首席医疗官和Ethicon集团公司全球管理委员会成员。在强生公司任职期间，他还在制药行业担任高级职务。Mahmoud博士在美国陆军（U.S.Army）服役10年，在陆军预备役部队（Army Reserves）再服役10年，达到中校军衔。在服兵役期间，Mahmoud博士担任多个病人护理、研究和学术职位，最终担任Walter Reed Army Institute of Research流行病学系主任。他发表了50多篇同行评议论文和教科书章节，并担任多个期刊和教科书的科学评审员。Mahmoud博士在哈佛大学公共卫生学院获得梦百合管理和政策硕士学位，在迈阿密大学获得医学博士学位。
- Ramy A. Mahmoud,has served as Optinose, Inc. Chief Executive Officer and as a member of Optinose, Inc. Board of Directors since January 2023. Prior to being appointed Chief Executive Officer, Dr. Mahmoud served as Optinose, Inc. President and Chief Operating Officer since 2010. Prior to joining Optinose, Inc. , Dr. Mahmoud spent 14 years at Johnson & Johnson, where he most recently served as Chief Medical Officer and a member of the Global Management Board of the Ethicon group of companies. During his tenure at Johnson & Johnson, he also held senior roles in the pharmaceutical sector. Dr. Mahmoud served for 10 years on active duty in the U.S. Army and an additional 10 years in the Army Reserves, achieving the rank of Lieutenant Colonel. During his military service, Dr. Mahmoud held various patient care, research, and academic positions, culminating in his position as the head of the Department of Epidemiology at the Walter Reed Army Institute of Research. He has published more than 80 peer-reviewed papers and textbook chapters, and has served as a scientific reviewer for a number of journals and textbooks. Dr. Mahmoud earned a Master of Healthcare Management and Policy degree from the Harvard School of Public Health and an M.D. from the University of Miami. He has earned board certification in both Public Health/Preventive Medicine and in Internal Medicine.
- R. John Fletcher
-
R. John Fletcher目前担任Fletcher Spaght Inc.（他于1983年创立的战略咨询和风险投资公司）的首席执行官和董事总经理。他于2002年加入上市医疗设备公司Spectranetics Corporation的董事会，并于2010年至2017年担任董事会主席。由于他在Spectranetics的工作，Fletcher先生被National Association of Corporate Directors NACD任命为2018年的年度董事。他目前任职于Axcelis Corporation, MRI Interventions, Inc.的董事会，以及Metabolon, Inc.的董事长。他是Dartmouth College，Thayer School of Engineering /Tuck School of Business的企业合作委员会名誉主席，Beth Israel Deaconess Medical Center和麻省理工学院（MIT） Whitehead Institute的顾问委员会成员。他持有Southern Illinois University的工商管理硕士学位和George Washington University的市场营销工商管理硕士学位。
R. John Fletcher currently serves as CEO and Managing Director of Fletcher Spaght Inc., a strategy consulting and venture capital firm which he founded in 1983. Mr. Fletcher joined the Board of Directors of publicly-traded medical device company Spectranetics Corporation in 2002 and served as Chairman of the Board from 2010-2017. Mr. Fletcher was named 2018 Director of the Year by The National Association of Corporate Directors NACD for his work at Spectranetics. Mr. Fletcher currently serves on the Board of Directors of Axcelis Corporation, MRI Interventions, Inc and is Chairman of Metabolon, Inc. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT. Mr. Fletcher received his MBA from Southern Illinois University and a BBA in Marketing from George Washington University. - R. John Fletcher目前担任Fletcher Spaght Inc.（他于1983年创立的战略咨询和风险投资公司）的首席执行官和董事总经理。他于2002年加入上市医疗设备公司Spectranetics Corporation的董事会，并于2010年至2017年担任董事会主席。由于他在Spectranetics的工作，Fletcher先生被National Association of Corporate Directors NACD任命为2018年的年度董事。他目前任职于Axcelis Corporation, MRI Interventions, Inc.的董事会，以及Metabolon, Inc.的董事长。他是Dartmouth College，Thayer School of Engineering /Tuck School of Business的企业合作委员会名誉主席，Beth Israel Deaconess Medical Center和麻省理工学院（MIT） Whitehead Institute的顾问委员会成员。他持有Southern Illinois University的工商管理硕士学位和George Washington University的市场营销工商管理硕士学位。
- R. John Fletcher currently serves as CEO and Managing Director of Fletcher Spaght Inc., a strategy consulting and venture capital firm which he founded in 1983. Mr. Fletcher joined the Board of Directors of publicly-traded medical device company Spectranetics Corporation in 2002 and served as Chairman of the Board from 2010-2017. Mr. Fletcher was named 2018 Director of the Year by The National Association of Corporate Directors NACD for his work at Spectranetics. Mr. Fletcher currently serves on the Board of Directors of Axcelis Corporation, MRI Interventions, Inc and is Chairman of Metabolon, Inc. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT. Mr. Fletcher received his MBA from Southern Illinois University and a BBA in Marketing from George Washington University.
- Eric Bednarski
-
Eric Bednarski，我们公司的非独立非执行董事，目前担任MVM Partners LLP的合伙人。在2008年加入MVM之前，他是Advent 医疗保健Ventures的合伙人和Advent International Corporation的负责人。任职Advent公司之前，他曾担任Silicon Valley Bank的公司财务集团的董事。Bednarski博士在布朗大学获得神经科学学士学位，在加州大学欧文分校获得生物科学博士学位。
Eric Bednarski,has served as a director of Optinose, Inc. since December 2021. Dr. Bednarski has served as a partner at MVM Partners LLP (MVM), a healthcare growth equity firm, since 2008. Before joining MVM, Dr. Bednarski was a Partner at Advent Healthcare Ventures and a Principal at Advent International Corporation. Dr. Bednarski currently serves on the Board of Directors of MDxHealth SA (NASDAQ: MDXH) a commercial stage precision diagnostics company, Neurolens, Inc., a developer of prescription lenses, and Vero Biotech, Inc., a biotechnology company focused on cardiopulmonary conditions. Dr. Bednarski has a B.S. in Neural Science from Brown University and a Ph.D. in Biological Science from the University of California, Irvine. - Eric Bednarski，我们公司的非独立非执行董事，目前担任MVM Partners LLP的合伙人。在2008年加入MVM之前，他是Advent 医疗保健Ventures的合伙人和Advent International Corporation的负责人。任职Advent公司之前，他曾担任Silicon Valley Bank的公司财务集团的董事。Bednarski博士在布朗大学获得神经科学学士学位，在加州大学欧文分校获得生物科学博士学位。
- Eric Bednarski,has served as a director of Optinose, Inc. since December 2021. Dr. Bednarski has served as a partner at MVM Partners LLP (MVM), a healthcare growth equity firm, since 2008. Before joining MVM, Dr. Bednarski was a Partner at Advent Healthcare Ventures and a Principal at Advent International Corporation. Dr. Bednarski currently serves on the Board of Directors of MDxHealth SA (NASDAQ: MDXH) a commercial stage precision diagnostics company, Neurolens, Inc., a developer of prescription lenses, and Vero Biotech, Inc., a biotechnology company focused on cardiopulmonary conditions. Dr. Bednarski has a B.S. in Neural Science from Brown University and a Ph.D. in Biological Science from the University of California, Irvine.
- Eric Bednarski
-
Eric Bednarski，自2021年12月起担任Optinose，Inc.的董事。Bednarski博士自2008年起担任MVM Partners LLP（MVM）的合伙人，该公司是一家医疗保健成长型股票公司。在加入MVM之前，Bednarski博士是Advent Healthcare Ventures的合伙人，也是Advent International Corporation的负责人。Bednarski博士目前在MDxHealth SA（NASDAQ：MDXH）（一家商业阶段的精准诊断公司）、Neurolens，Inc.（一家处方镜片开发商）和Vero Biotech，Inc.（一家专注于心肺疾病的生物技术公司）的董事会任职。Bednarski博士拥有布朗大学神经科学学士学位和加州大学欧文分校生物科学博士学位。
Eric Bednarski,has served as a director of Optinose, Inc. since December 2021. Dr. Bednarski has served as a partner at MVM Partners LLP (MVM), a healthcare growth equity firm, since 2008. Before joining MVM, Dr. Bednarski was a Partner at Advent Healthcare Ventures and a Principal at Advent International Corporation. Dr. Bednarski currently serves on the Board of Directors of MDxHealth SA (NASDAQ: MDXH) a commercial stage precision diagnostics company, Neurolens, Inc., a developer of prescription lenses, and Vero Biotech, Inc., a biotechnology company focused on cardiopulmonary conditions. Dr. Bednarski has a B.S. in Neural Science from Brown University and a Ph.D. in Biological Science from the University of California, Irvine. - Eric Bednarski，自2021年12月起担任Optinose，Inc.的董事。Bednarski博士自2008年起担任MVM Partners LLP（MVM）的合伙人，该公司是一家医疗保健成长型股票公司。在加入MVM之前，Bednarski博士是Advent Healthcare Ventures的合伙人，也是Advent International Corporation的负责人。Bednarski博士目前在MDxHealth SA（NASDAQ：MDXH）（一家商业阶段的精准诊断公司）、Neurolens，Inc.（一家处方镜片开发商）和Vero Biotech，Inc.（一家专注于心肺疾病的生物技术公司）的董事会任职。Bednarski博士拥有布朗大学神经科学学士学位和加州大学欧文分校生物科学博士学位。
- Eric Bednarski,has served as a director of Optinose, Inc. since December 2021. Dr. Bednarski has served as a partner at MVM Partners LLP (MVM), a healthcare growth equity firm, since 2008. Before joining MVM, Dr. Bednarski was a Partner at Advent Healthcare Ventures and a Principal at Advent International Corporation. Dr. Bednarski currently serves on the Board of Directors of MDxHealth SA (NASDAQ: MDXH) a commercial stage precision diagnostics company, Neurolens, Inc., a developer of prescription lenses, and Vero Biotech, Inc., a biotechnology company focused on cardiopulmonary conditions. Dr. Bednarski has a B.S. in Neural Science from Brown University and a Ph.D. in Biological Science from the University of California, Irvine.
- Kyle Dempsey
-
Kyle Dempsey，自2021年12月起担任Optinose，Inc.的董事。自2017年以来，Dempsey博士一直担任医疗保健成长型股权公司MVM Partners LLP（MVM）的合伙人。在加入MVM之前，Dempsey博士于2016年至2017年担任贝恩公司的顾问，主要从事医疗保健实践工作，为医疗器械和医疗保健提供商客户提供商业化和业务发展项目的支持。Dempsey博士是GT Medical Technologies，Inc.（一家专注于脑肿瘤治疗的私营公司）和HLS Therapeutics Inc.（OTC：HLTRF）（一家专注于中枢神经系统和心血管市场的制药公司）的董事会和审计委员会成员。他获得了哈佛医学院的医学博士学位和哈佛商学院的工商管理硕士学位。他还拥有鲍登学院的生物化学学士学位。
Kyle Dempsey,has served as a director of Optinose, Inc. since December 2021. Dr. Dempsey has served as a partner at MVM Partners LLP (MVM), a healthcare growth equity firm, since 2017. Before joining MVM, Dr. Dempsey was a consultant at Bain & Company from 2016 to 2017, working mainly in the healthcare practice to support medical device and healthcare provider clients with commercialization and business development projects. Dr. Dempsey is a member of the board of directors and audit committee at GT Medical Technologies, Inc., a private company focused on the treatment of brain tumors, and HLS Therapeutics Inc. (OTC: HLTRF), a pharmaceutical company focusing on central nervous system and cardiovascular markets. He received his M.D. from Harvard Medical School and his M.B.A. from Harvard Business School. He also holds a B.A. in biochemistry from Bowdoin College. - Kyle Dempsey，自2021年12月起担任Optinose，Inc.的董事。自2017年以来，Dempsey博士一直担任医疗保健成长型股权公司MVM Partners LLP（MVM）的合伙人。在加入MVM之前，Dempsey博士于2016年至2017年担任贝恩公司的顾问，主要从事医疗保健实践工作，为医疗器械和医疗保健提供商客户提供商业化和业务发展项目的支持。Dempsey博士是GT Medical Technologies，Inc.（一家专注于脑肿瘤治疗的私营公司）和HLS Therapeutics Inc.（OTC：HLTRF）（一家专注于中枢神经系统和心血管市场的制药公司）的董事会和审计委员会成员。他获得了哈佛医学院的医学博士学位和哈佛商学院的工商管理硕士学位。他还拥有鲍登学院的生物化学学士学位。
- Kyle Dempsey,has served as a director of Optinose, Inc. since December 2021. Dr. Dempsey has served as a partner at MVM Partners LLP (MVM), a healthcare growth equity firm, since 2017. Before joining MVM, Dr. Dempsey was a consultant at Bain & Company from 2016 to 2017, working mainly in the healthcare practice to support medical device and healthcare provider clients with commercialization and business development projects. Dr. Dempsey is a member of the board of directors and audit committee at GT Medical Technologies, Inc., a private company focused on the treatment of brain tumors, and HLS Therapeutics Inc. (OTC: HLTRF), a pharmaceutical company focusing on central nervous system and cardiovascular markets. He received his M.D. from Harvard Medical School and his M.B.A. from Harvard Business School. He also holds a B.A. in biochemistry from Bowdoin College.
- R. John Fletcher
-
R. John Fletcher，自2022年4月起担任Optinose，Inc.董事。1983年，弗莱彻先生创立了Fletcher Spaght，Inc.，这是一家为医疗保健公司提供以增长为重点的战略援助的咨询公司，自成立以来一直担任其首席执行官。自2001年以来，Fletcher先生还担任风险投资基金Fletcher Spaght Ventures的管理合伙人。弗莱彻先生目前和过去的董事会经验包括上市公司和私营公司。Fletcher先生目前担任Repro Med Systems, Inc.（d/b/a KORU Medical Systems，Inc.）（NASDAQ：KRMD）的董事会主席，该公司是一家专有的便携式和创新医疗设备制造公司。Fletcher先生还担任ClearPoint Neuro, Inc.（NASDAQ：CLPT）（一家全球治疗赋能平台公司）和私营健康技术公司Metabolon，Inc.的董事会主席。Fletcher先生此前曾任职于医疗设备公司Spectranetics Corporation、生物技术公司AutoImmune，Inc.、半导体芯片公司Axcelis Technologies, Inc.、先进成像公司Fischer Imaging Corp.、专注于传染病治疗解决方案的生物技术公司Panacos Pharmaceuticals Inc.、植入技术公司NMT Medical Inc.的董事会，所有这些公司都是或曾经是上市公司，并且是GlycoFi，Inc.和Quick Study Radiology Inc.的董事会成员，这两家公司都是或曾经是私营公司。此外，弗莱彻先生还曾在许多学术和非营利机构的董事会任职。Fletcher先生参与了Koninklijke Philips N.V.（皇家飞利浦）以20亿美元收购Spectranetics的交易以及默克制药公司以4亿美元收购GlycoFi的交易，并在2018年获得了美国公司董事协会（NACD）年度董事奖，特别是由于他在Spectranetics和AxCelis的转型中所做的工作。他是达特茅斯学院Thayer工程学院/塔克商学院企业协作委员会的名誉主席，并担任贝斯以色列女执事医疗中心和麻省理工学院怀特黑德研究所的顾问委员会成员。Fletcher先生毕业于南伊利诺伊大学（MBA）、中密歇根大学（国际金融硕士学位）和乔治华盛顿大学（市场营销BBA），曾是国际商务讲师，是沃顿商学院的博士候选人。他还曾在美国空军担任机长和喷气式飞机飞行员教官。
R. John Fletcher,has served as a director of Optinose, Inc. since April 2022. In 1983, Mr. Fletcher founded Fletcher Spaght, Inc., a consulting firm that provides growth-focused strategy assistance to healthcare companies, and since its founding has served as its Chief Executive Officer. Since 2001, Mr. Fletcher has also served as the Managing Partner of Fletcher Spaght Ventures, a venture capital fund. Mr. Fletcher's current and past board experience includes both public and private companies. Mr. Fletcher currently serves as the board chairman of Repro Med Systems, Inc. (d/b/a KORU Medical Systems)(NASDAQ: KRMD), a proprietary portable and innovative medical devices manufacturing company. Mr. Fletcher also serves as the board chairman of Clearpoint Neuro, Inc. (NASDAQ:CLPT), a global therapy-enabling platform company, and privately-held Metabolon, Inc. a health technology company. Mr. Fletcher previously served on the boards of Spectranetics Corporation, a medical device company, Autoimmune, Inc., a biotechnology technology company, Axcelis Technologies, Inc., a semiconductor chip company, Fischer Imaging Corp., an advanced imaging company, Panacos Pharmaceuticals Inc., a biotechnology company focused on therapeutic solutions for infectious disease, NMT Medical Inc., an implant technology company, all of which are or were public companies, and on the board of GlycoFi, Inc. and Quick Study Radiology Inc., both of which are or were private companies. In addition, Mr. Fletcher has served on the boards of many academic and non-profit institutions. Mr. Fletcher worked on the $2 billion acquisition of Spectranetics by Koninklijke Philips N.V. (Royal Philips) and the $400 million acquisition of GlycoFi by Merck & Co., Inc., and received the National Association of Corporate Directors (NACD) Director of the Year Award in 2018 specifically due to his work with the turnarounds of Spectranetics and Axcelis. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT. Mr. Fletcher is a graduate of Southern Illinois University (MBA), Central Michigan University (Master's Degree in International Finance), and George Washington University (BBA in Marketing) and was an instructor in International Business and was a PhD candidate at the Wharton School of Business. He also served as a Captain and jet pilot instructor in the United States Air Force. - R. John Fletcher，自2022年4月起担任Optinose，Inc.董事。1983年，弗莱彻先生创立了Fletcher Spaght，Inc.，这是一家为医疗保健公司提供以增长为重点的战略援助的咨询公司，自成立以来一直担任其首席执行官。自2001年以来，Fletcher先生还担任风险投资基金Fletcher Spaght Ventures的管理合伙人。弗莱彻先生目前和过去的董事会经验包括上市公司和私营公司。Fletcher先生目前担任Repro Med Systems, Inc.（d/b/a KORU Medical Systems，Inc.）（NASDAQ：KRMD）的董事会主席，该公司是一家专有的便携式和创新医疗设备制造公司。Fletcher先生还担任ClearPoint Neuro, Inc.（NASDAQ：CLPT）（一家全球治疗赋能平台公司）和私营健康技术公司Metabolon，Inc.的董事会主席。Fletcher先生此前曾任职于医疗设备公司Spectranetics Corporation、生物技术公司AutoImmune，Inc.、半导体芯片公司Axcelis Technologies, Inc.、先进成像公司Fischer Imaging Corp.、专注于传染病治疗解决方案的生物技术公司Panacos Pharmaceuticals Inc.、植入技术公司NMT Medical Inc.的董事会，所有这些公司都是或曾经是上市公司，并且是GlycoFi，Inc.和Quick Study Radiology Inc.的董事会成员，这两家公司都是或曾经是私营公司。此外，弗莱彻先生还曾在许多学术和非营利机构的董事会任职。Fletcher先生参与了Koninklijke Philips N.V.（皇家飞利浦）以20亿美元收购Spectranetics的交易以及默克制药公司以4亿美元收购GlycoFi的交易，并在2018年获得了美国公司董事协会（NACD）年度董事奖，特别是由于他在Spectranetics和AxCelis的转型中所做的工作。他是达特茅斯学院Thayer工程学院/塔克商学院企业协作委员会的名誉主席，并担任贝斯以色列女执事医疗中心和麻省理工学院怀特黑德研究所的顾问委员会成员。Fletcher先生毕业于南伊利诺伊大学（MBA）、中密歇根大学（国际金融硕士学位）和乔治华盛顿大学（市场营销BBA），曾是国际商务讲师，是沃顿商学院的博士候选人。他还曾在美国空军担任机长和喷气式飞机飞行员教官。
- R. John Fletcher,has served as a director of Optinose, Inc. since April 2022. In 1983, Mr. Fletcher founded Fletcher Spaght, Inc., a consulting firm that provides growth-focused strategy assistance to healthcare companies, and since its founding has served as its Chief Executive Officer. Since 2001, Mr. Fletcher has also served as the Managing Partner of Fletcher Spaght Ventures, a venture capital fund. Mr. Fletcher's current and past board experience includes both public and private companies. Mr. Fletcher currently serves as the board chairman of Repro Med Systems, Inc. (d/b/a KORU Medical Systems)(NASDAQ: KRMD), a proprietary portable and innovative medical devices manufacturing company. Mr. Fletcher also serves as the board chairman of Clearpoint Neuro, Inc. (NASDAQ:CLPT), a global therapy-enabling platform company, and privately-held Metabolon, Inc. a health technology company. Mr. Fletcher previously served on the boards of Spectranetics Corporation, a medical device company, Autoimmune, Inc., a biotechnology technology company, Axcelis Technologies, Inc., a semiconductor chip company, Fischer Imaging Corp., an advanced imaging company, Panacos Pharmaceuticals Inc., a biotechnology company focused on therapeutic solutions for infectious disease, NMT Medical Inc., an implant technology company, all of which are or were public companies, and on the board of GlycoFi, Inc. and Quick Study Radiology Inc., both of which are or were private companies. In addition, Mr. Fletcher has served on the boards of many academic and non-profit institutions. Mr. Fletcher worked on the $2 billion acquisition of Spectranetics by Koninklijke Philips N.V. (Royal Philips) and the $400 million acquisition of GlycoFi by Merck & Co., Inc., and received the National Association of Corporate Directors (NACD) Director of the Year Award in 2018 specifically due to his work with the turnarounds of Spectranetics and Axcelis. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT. Mr. Fletcher is a graduate of Southern Illinois University (MBA), Central Michigan University (Master's Degree in International Finance), and George Washington University (BBA in Marketing) and was an instructor in International Business and was a PhD candidate at the Wharton School of Business. He also served as a Captain and jet pilot instructor in the United States Air Force.
- Sandra L. Helton
-
Sandra L. Helton，自2018年2月起担任Optinose，Inc.董事。到2022年5月，Helton女士一直在全球多元化金融机构信安金融（Principal）的董事会任职，担任审计委员会主席，并在Principal的执行委员会和财务委员会任职，此前她曾担任该委员会主席。在公司于2022年10月私有化之前，Helton女士还曾在全球动物保健企业Covetrus的董事会任职，并担任其审计委员会主席以及提名和治理委员会成员。在2016年11月收购利盟国际公司之前，她曾在这些公司的董事会以及财务和审计委员会任职。在LabCorp于2015年收购该公司之前，Helton女士还曾在全球领先的药物开发服务公司科文司的董事会任职。她担任财务和审计委员会主席，并在科文斯的提名和治理委员会任职。Helton女士从1998年到2006年担任Telephone and Data Systems，Inc.（TDS）的执行副总裁兼首席财务官和董事会成员。她的职责包括战略规划、财务和信息系统等职能。Helton女士还曾在TDS的上市子公司United States Cellular Corporation和Aerial Corporation的董事会任职。在加入TDS之前，Helton女士是副总裁，康柏电脑公司的公司财务总监。在加入康柏公司之前，赫尔顿女士在康宁公司任职的26年期间担任过十几个责任越来越大的职位。赫尔顿女士在西北纪念基金会董事会任职。此前，她曾在西北纪念医疗保健公司（Northwestern Memorial Health Care）的董事会任职，该公司是一家国家认可的学术医疗中心，曾担任审计委员会主席，并且是执行委员会、财务委员会和投资委员会的成员。Helton女士拥有麻省理工学院斯隆管理学院金融学硕士学位，并毕业于肯塔基大学数学学士学位。
Sandra L. Helton,has served as a director of Optinose, Inc. since February 2018. Through May 2022 Ms. Helton served on the Board of Directors of Principal Financial Group (Principal), a global diversified financial institution, where she chaired the Audit Committee and served on Principal's Executive Committee and Finance Committee, which she previously chaired. Prior to the company going private in October 2022, Ms. Helton also served on the Board of Directors of Covetrus, a worldwide animal health business and chaired their Audit Committee and served on their Nominating and Governance Committee. Prior to the acquisition of Lexmark International Inc. in November 2016, she served on their Board of Directors and Finance and Audit Committee. Ms. Helton also served on the board of Covance Inc., a leading global drug development services company, prior to LabCorp acquiring the company in 2015. She chaired the Finance and Audit Committee and served on the Nominating and Governance Committee of Covance. Ms. Helton was Executive Vice President and Chief Financial Officer, and member of the Board of Directors, of Telephone and Data Systems, Inc. (TDS) from 1998 through 2006. Her responsibilities included strategic planning, finance and information systems, among other functions. Ms. Helton also served on the Boards of United States Cellular Corporation and Aerial Corporation, TDS's publicly traded subsidiaries. Before TDS, Ms. Helton was Vice President, Corporate Controller of Compaq Computer Corporation. Prior to Compaq, Ms. Helton held over a dozen increasingly responsible positions during her 26-year tenure with Corning Incorporated. Ms. Helton serves on the Board of Northwestern Memorial Foundation. She previously served on the Board of Northwestern Memorial Health Care, a nationally recognized academic medical center, where she chaired the Audit Committee and was a member of the Executive, Finance and Investment Committees. Ms. Helton holds an S.M. in Finance from Massachusetts Institute of Technology's Sloan School of Management and graduated with a B.S. in Mathematics from the University of Kentucky. - Sandra L. Helton，自2018年2月起担任Optinose，Inc.董事。到2022年5月，Helton女士一直在全球多元化金融机构信安金融（Principal）的董事会任职，担任审计委员会主席，并在Principal的执行委员会和财务委员会任职，此前她曾担任该委员会主席。在公司于2022年10月私有化之前，Helton女士还曾在全球动物保健企业Covetrus的董事会任职，并担任其审计委员会主席以及提名和治理委员会成员。在2016年11月收购利盟国际公司之前，她曾在这些公司的董事会以及财务和审计委员会任职。在LabCorp于2015年收购该公司之前，Helton女士还曾在全球领先的药物开发服务公司科文司的董事会任职。她担任财务和审计委员会主席，并在科文斯的提名和治理委员会任职。Helton女士从1998年到2006年担任Telephone and Data Systems，Inc.（TDS）的执行副总裁兼首席财务官和董事会成员。她的职责包括战略规划、财务和信息系统等职能。Helton女士还曾在TDS的上市子公司United States Cellular Corporation和Aerial Corporation的董事会任职。在加入TDS之前，Helton女士是副总裁，康柏电脑公司的公司财务总监。在加入康柏公司之前，赫尔顿女士在康宁公司任职的26年期间担任过十几个责任越来越大的职位。赫尔顿女士在西北纪念基金会董事会任职。此前，她曾在西北纪念医疗保健公司（Northwestern Memorial Health Care）的董事会任职，该公司是一家国家认可的学术医疗中心，曾担任审计委员会主席，并且是执行委员会、财务委员会和投资委员会的成员。Helton女士拥有麻省理工学院斯隆管理学院金融学硕士学位，并毕业于肯塔基大学数学学士学位。
- Sandra L. Helton,has served as a director of Optinose, Inc. since February 2018. Through May 2022 Ms. Helton served on the Board of Directors of Principal Financial Group (Principal), a global diversified financial institution, where she chaired the Audit Committee and served on Principal's Executive Committee and Finance Committee, which she previously chaired. Prior to the company going private in October 2022, Ms. Helton also served on the Board of Directors of Covetrus, a worldwide animal health business and chaired their Audit Committee and served on their Nominating and Governance Committee. Prior to the acquisition of Lexmark International Inc. in November 2016, she served on their Board of Directors and Finance and Audit Committee. Ms. Helton also served on the board of Covance Inc., a leading global drug development services company, prior to LabCorp acquiring the company in 2015. She chaired the Finance and Audit Committee and served on the Nominating and Governance Committee of Covance. Ms. Helton was Executive Vice President and Chief Financial Officer, and member of the Board of Directors, of Telephone and Data Systems, Inc. (TDS) from 1998 through 2006. Her responsibilities included strategic planning, finance and information systems, among other functions. Ms. Helton also served on the Boards of United States Cellular Corporation and Aerial Corporation, TDS's publicly traded subsidiaries. Before TDS, Ms. Helton was Vice President, Corporate Controller of Compaq Computer Corporation. Prior to Compaq, Ms. Helton held over a dozen increasingly responsible positions during her 26-year tenure with Corning Incorporated. Ms. Helton serves on the Board of Northwestern Memorial Foundation. She previously served on the Board of Northwestern Memorial Health Care, a nationally recognized academic medical center, where she chaired the Audit Committee and was a member of the Executive, Finance and Investment Committees. Ms. Helton holds an S.M. in Finance from Massachusetts Institute of Technology's Sloan School of Management and graduated with a B.S. in Mathematics from the University of Kentucky.
- Tomas J. Heyman
-
Tomas J. Heyman，自2020年12月起担任Optinose，Inc.的董事。在强生三十七年的职业生涯中，Heyman先生曾担任多个领导职务，涵盖法律、研发、业务发展、一般企业管理和股权投资。最近，从2015年到2019年，海曼先生担任强生旗下风险投资集团JJDC的总裁，管理着约15亿美元的资本，并监督对120多家公司的投资。在领导JJDC之前，Heyman先生为强生的制药集团杨森（Janssen）领导了二十三年的业务发展。Heyman先生目前在心脏代谢生物技术公司Akero Therapeutics, Inc.（NASDAQ：AKRO）的董事会任职，担任Akero提名和公司治理委员会主席，并且是Akero审计委员会成员；在Invivyd，Inc.（前身为Adagio Therapeutics Inc.）（NASDAQ：IVVD）的董事会任职，该公司是一家专注于基于抗体的疗法的发现、开发和商业化的生物制药公司，担任Invivyd薪酬委员会主席，并且是Invivyd审计委员会成员；在开发肿瘤的生物技术公司Xilio Therapeutics, Inc.丨（NASDAQ：XLO）的董事会任职他担任Xilio提名和公司治理委员会主席，并且是Xilio审计委员会成员；在开发、制造和商业化治疗危及生命的疾病的新疗法的生物技术公司传奇生物技术公司（纳斯达克股票代码：LEGN）的董事会任职；在私营临床阶段制药公司Venatorx Pharmaceuticals的董事会任职，担任非执行主席。Heyman先生毕业于比利时K.U.鲁汶大学，获得法律硕士学位。他继续在瑞士日内瓦攻读国际法研究生，并在比利时安特卫普大学攻读企业管理研究生。
Tomas J. Heyman,has served as a director of Optinose, Inc. since December 2020. Mr. Heyman held a diverse range of leadership roles across legal, R&D, business development, general corporate management, and equity investments during his thirty-seven-year career with Johnson & Johnson. Most recently, from 2015 to 2019, Mr. Heyman served as president of JJDC, the venture capital group within Johnson & Johnson, where he managed approximately $1.5 billion of capital and oversaw investments in more than 120 companies. Prior to leading JJDC, Mr. Heyman led business development for Johnson & Johnson's pharmaceutical group, Janssen, for twenty-three years. Mr. Heyman currently serves on the board of directors for Akero Therapeutics, Inc. (NASDAQ: AKRO), a cardio-metabolic biotechnology company, where he chairs Akero's Nominating and Corporate Governance Committee and is a member of Akero's Audit Committee; on the board of directors of Invivyd, Inc. (formerly Adagio Therapeutics Inc.) (NASDAQ: IVVD), a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies, where he chairs Invivyd's Compensation Committee and is a member of Invivyd's Audit Committee; on the board of directors of Xilio Therapeutics, Inc. (NASDAQ: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies, where he chairs Xilio's Nominating and Corporate Governance Committee and is a member of Xilio's Audit Committee; on the board of directors of Legend Biotech Corporation (NASDAQ: LEGN), a biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases; on board of directors of Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company, where he serves as Non-Executive Chairman. Mr. Heyman graduated as Master of Law from the K.U. Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium. - Tomas J. Heyman，自2020年12月起担任Optinose，Inc.的董事。在强生三十七年的职业生涯中，Heyman先生曾担任多个领导职务，涵盖法律、研发、业务发展、一般企业管理和股权投资。最近，从2015年到2019年，海曼先生担任强生旗下风险投资集团JJDC的总裁，管理着约15亿美元的资本，并监督对120多家公司的投资。在领导JJDC之前，Heyman先生为强生的制药集团杨森（Janssen）领导了二十三年的业务发展。Heyman先生目前在心脏代谢生物技术公司Akero Therapeutics, Inc.（NASDAQ：AKRO）的董事会任职，担任Akero提名和公司治理委员会主席，并且是Akero审计委员会成员；在Invivyd，Inc.（前身为Adagio Therapeutics Inc.）（NASDAQ：IVVD）的董事会任职，该公司是一家专注于基于抗体的疗法的发现、开发和商业化的生物制药公司，担任Invivyd薪酬委员会主席，并且是Invivyd审计委员会成员；在开发肿瘤的生物技术公司Xilio Therapeutics, Inc.丨（NASDAQ：XLO）的董事会任职他担任Xilio提名和公司治理委员会主席，并且是Xilio审计委员会成员；在开发、制造和商业化治疗危及生命的疾病的新疗法的生物技术公司传奇生物技术公司（纳斯达克股票代码：LEGN）的董事会任职；在私营临床阶段制药公司Venatorx Pharmaceuticals的董事会任职，担任非执行主席。Heyman先生毕业于比利时K.U.鲁汶大学，获得法律硕士学位。他继续在瑞士日内瓦攻读国际法研究生，并在比利时安特卫普大学攻读企业管理研究生。
- Tomas J. Heyman,has served as a director of Optinose, Inc. since December 2020. Mr. Heyman held a diverse range of leadership roles across legal, R&D, business development, general corporate management, and equity investments during his thirty-seven-year career with Johnson & Johnson. Most recently, from 2015 to 2019, Mr. Heyman served as president of JJDC, the venture capital group within Johnson & Johnson, where he managed approximately $1.5 billion of capital and oversaw investments in more than 120 companies. Prior to leading JJDC, Mr. Heyman led business development for Johnson & Johnson's pharmaceutical group, Janssen, for twenty-three years. Mr. Heyman currently serves on the board of directors for Akero Therapeutics, Inc. (NASDAQ: AKRO), a cardio-metabolic biotechnology company, where he chairs Akero's Nominating and Corporate Governance Committee and is a member of Akero's Audit Committee; on the board of directors of Invivyd, Inc. (formerly Adagio Therapeutics Inc.) (NASDAQ: IVVD), a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies, where he chairs Invivyd's Compensation Committee and is a member of Invivyd's Audit Committee; on the board of directors of Xilio Therapeutics, Inc. (NASDAQ: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies, where he chairs Xilio's Nominating and Corporate Governance Committee and is a member of Xilio's Audit Committee; on the board of directors of Legend Biotech Corporation (NASDAQ: LEGN), a biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases; on board of directors of Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company, where he serves as Non-Executive Chairman. Mr. Heyman graduated as Master of Law from the K.U. Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium.
- Catherine Owen
-
Catherine Owen，自2020年7月起担任Optinose，Inc.的董事。Owen女士是百时美施贵宝（BMS）主要市场高级副总裁，负责监督该业务在18个国家的商业运营，包括日本、德国、法国以及欧洲其他国家。Owen女士于2019年从强生加入BMS，最近一次是在2018年至2019年担任杨森免疫学北美区总裁，该公司推出了治疗克罗恩病和银屑病的新产品，并领导了强生生物仿制药战略的制定。在领导免疫学之前，欧文女士于2016年至2018年担任美国传染病业务总裁，负责HIV、RSV、流感和乙型肝炎管道。在此之前，Owen女士曾在强生的多个职能和业务部门工作，并在欧洲和美国领导了多个产品的发布。Owen女士于1992年在伦敦的阿斯利康开始了她的制药行业职业生涯，担任生产支持药剂师。Owen女士在曼彻斯特大学获得了药学理学学士学位，并完成了注册药学学位，并且是皇家药学协会MRPHS的成员。2019年，为了表彰她作为人才开发者所做的努力，医疗保健女企业家协会（HBA）将欧文女士评为HBA杰出人物。
Catherine Owen,has served as a director of Optinose, Inc. since July 2020. Ms. Owen is Senior Vice President, Major Markets at Bristol-Myers Squibb (BMS), overseeing commercial operations for the business in 18 countries including Japan, Germany, France, and others across Europe. Ms. Owen joined BMS in 2019 from Johnson & Johnson, where she served most recently as President of Janssen Immunology North America from 2018 to 2019, which launched new products in Crohn's disease and psoriasis and led the development of J&J's biosimilars strategy. Prior to leading Immunology, Ms. Owen was the President of the Infectious Diseases business in the US from 2016 to 2018, responsible for the HIV, RSV, Flu, and Hepatitis B pipeline. Prior to that Ms. Owen worked in various functions and businesses at J&J and led the launches of multiple products in both Europe and the US. Ms. Owen began her career in the pharmaceutical industry in 1992 at AstraZeneca in London as a production support pharmacist. Ms. Owen earned her Bachelor of Science degree in pharmacy from the University of Manchester and completed her registered pharmacy degree and was a member of the Royal Pharmaceutical Society, MRPhs. In 2019, in recognition of her efforts as a developer of talent, the Healthcare Businesswomen's Association (HBA) named Ms. Owen an HBA Luminary. - Catherine Owen，自2020年7月起担任Optinose，Inc.的董事。Owen女士是百时美施贵宝（BMS）主要市场高级副总裁，负责监督该业务在18个国家的商业运营，包括日本、德国、法国以及欧洲其他国家。Owen女士于2019年从强生加入BMS，最近一次是在2018年至2019年担任杨森免疫学北美区总裁，该公司推出了治疗克罗恩病和银屑病的新产品，并领导了强生生物仿制药战略的制定。在领导免疫学之前，欧文女士于2016年至2018年担任美国传染病业务总裁，负责HIV、RSV、流感和乙型肝炎管道。在此之前，Owen女士曾在强生的多个职能和业务部门工作，并在欧洲和美国领导了多个产品的发布。Owen女士于1992年在伦敦的阿斯利康开始了她的制药行业职业生涯，担任生产支持药剂师。Owen女士在曼彻斯特大学获得了药学理学学士学位，并完成了注册药学学位，并且是皇家药学协会MRPHS的成员。2019年，为了表彰她作为人才开发者所做的努力，医疗保健女企业家协会（HBA）将欧文女士评为HBA杰出人物。
- Catherine Owen,has served as a director of Optinose, Inc. since July 2020. Ms. Owen is Senior Vice President, Major Markets at Bristol-Myers Squibb (BMS), overseeing commercial operations for the business in 18 countries including Japan, Germany, France, and others across Europe. Ms. Owen joined BMS in 2019 from Johnson & Johnson, where she served most recently as President of Janssen Immunology North America from 2018 to 2019, which launched new products in Crohn's disease and psoriasis and led the development of J&J's biosimilars strategy. Prior to leading Immunology, Ms. Owen was the President of the Infectious Diseases business in the US from 2016 to 2018, responsible for the HIV, RSV, Flu, and Hepatitis B pipeline. Prior to that Ms. Owen worked in various functions and businesses at J&J and led the launches of multiple products in both Europe and the US. Ms. Owen began her career in the pharmaceutical industry in 1992 at AstraZeneca in London as a production support pharmacist. Ms. Owen earned her Bachelor of Science degree in pharmacy from the University of Manchester and completed her registered pharmacy degree and was a member of the Royal Pharmaceutical Society, MRPhs. In 2019, in recognition of her efforts as a developer of talent, the Healthcare Businesswomen's Association (HBA) named Ms. Owen an HBA Luminary.
- Sandra L. Helton
-
Sandra L. Helton 从1998年到2006年一直担任Telephone and Data Systems, Inc. "TDS"的执行副总裁兼首席财务官。该公司是一个多元化的电信组织，包括美国移动公司（United States Cellular Corporation）。截至2006年12月31日，TDS在36个州有700万客户/服务单位，年收入为45亿美元。Helton女士任职时负责金融、信息技术、战略规划、企业公关和公司秘书。在加入TDS之前，Helton女士在Corning Incorporated工作了26年。在那里她担任工程、战略和财务职位，包括从1991 年到1997年担任高级副总裁兼财务主管。她还从1997年到1998年担任康柏电脑公司（Compaq Computer Corporation ）的副总裁和公司财务总监。
Sandra L. Helton,has served as a director of Optinose, Inc. since February 2018. Through May 2022 Ms. Helton served on the Board of Directors of Principal Financial Group (Principal), a global diversified financial institution, where she chaired the Audit Committee and served on Principal's Executive Committee and Finance Committee, which she previously chaired. Prior to the company going private in October 2022, Ms. Helton also served on the Board of Directors of Covetrus, a worldwide animal health business and chaired their Audit Committee and served on their Nominating and Governance Committee. Prior to the acquisition of Lexmark International Inc. in November 2016, she served on their Board of Directors and Finance and Audit Committee. Ms. Helton also served on the board of Covance Inc., a leading global drug development services company, prior to LabCorp acquiring the company in 2015. She chaired the Finance and Audit Committee and served on the Nominating and Governance Committee of Covance. Ms. Helton was Executive Vice President and Chief Financial Officer, and member of the Board of Directors, of Telephone and Data Systems, Inc. (TDS) from 1998 through 2006. Her responsibilities included strategic planning, finance and information systems, among other functions. Ms. Helton also served on the Boards of United States Cellular Corporation and Aerial Corporation, TDS's publicly traded subsidiaries. Before TDS, Ms. Helton was Vice President, Corporate Controller of Compaq Computer Corporation. Prior to Compaq, Ms. Helton held over a dozen increasingly responsible positions during her 26-year tenure with Corning Incorporated. Ms. Helton serves on the Board of Northwestern Memorial Foundation. She previously served on the Board of Northwestern Memorial Health Care, a nationally recognized academic medical center, where she chaired the Audit Committee and was a member of the Executive, Finance and Investment Committees. Ms. Helton holds an S.M. in Finance from Massachusetts Institute of Technology's Sloan School of Management and graduated with a B.S. in Mathematics from the University of Kentucky. - Sandra L. Helton 从1998年到2006年一直担任Telephone and Data Systems, Inc. "TDS"的执行副总裁兼首席财务官。该公司是一个多元化的电信组织，包括美国移动公司（United States Cellular Corporation）。截至2006年12月31日，TDS在36个州有700万客户/服务单位，年收入为45亿美元。Helton女士任职时负责金融、信息技术、战略规划、企业公关和公司秘书。在加入TDS之前，Helton女士在Corning Incorporated工作了26年。在那里她担任工程、战略和财务职位，包括从1991 年到1997年担任高级副总裁兼财务主管。她还从1997年到1998年担任康柏电脑公司（Compaq Computer Corporation ）的副总裁和公司财务总监。
- Sandra L. Helton,has served as a director of Optinose, Inc. since February 2018. Through May 2022 Ms. Helton served on the Board of Directors of Principal Financial Group (Principal), a global diversified financial institution, where she chaired the Audit Committee and served on Principal's Executive Committee and Finance Committee, which she previously chaired. Prior to the company going private in October 2022, Ms. Helton also served on the Board of Directors of Covetrus, a worldwide animal health business and chaired their Audit Committee and served on their Nominating and Governance Committee. Prior to the acquisition of Lexmark International Inc. in November 2016, she served on their Board of Directors and Finance and Audit Committee. Ms. Helton also served on the board of Covance Inc., a leading global drug development services company, prior to LabCorp acquiring the company in 2015. She chaired the Finance and Audit Committee and served on the Nominating and Governance Committee of Covance. Ms. Helton was Executive Vice President and Chief Financial Officer, and member of the Board of Directors, of Telephone and Data Systems, Inc. (TDS) from 1998 through 2006. Her responsibilities included strategic planning, finance and information systems, among other functions. Ms. Helton also served on the Boards of United States Cellular Corporation and Aerial Corporation, TDS's publicly traded subsidiaries. Before TDS, Ms. Helton was Vice President, Corporate Controller of Compaq Computer Corporation. Prior to Compaq, Ms. Helton held over a dozen increasingly responsible positions during her 26-year tenure with Corning Incorporated. Ms. Helton serves on the Board of Northwestern Memorial Foundation. She previously served on the Board of Northwestern Memorial Health Care, a nationally recognized academic medical center, where she chaired the Audit Committee and was a member of the Executive, Finance and Investment Committees. Ms. Helton holds an S.M. in Finance from Massachusetts Institute of Technology's Sloan School of Management and graduated with a B.S. in Mathematics from the University of Kentucky.
- Joseph C. Scodari
-
Joseph C. Scodari曾为Johnson & Johnson医药集团全球总裁，一家多元化医疗公司。自2005年3月至2008年3月为"J&J”执行委员。自2003年至2005年3月Scodari先生为J&J生物医药公司集团总裁。Scodari先生于1999年加入J&J公司并自J&J公司收购Centocor公司后，任Centocor董事长及首席营运官。Scodari先生曾为Actelion医药有限公司（医药公司）董事，直至2011年5月。Scodari先生曾任Endo医疗公司董事，该公司自2013年12月发展成为一家多远化医疗健康服务公司。Scodari先生自2008年5月成为Covance公司董事会成员。
Joseph C. Scodari,has served as Chairman of Optinose, Inc. Board of Directors since October 2017. Mr. Scodari was Worldwide Chairman, Pharmaceuticals Group, of Johnson & Johnson, and a member of Johnson & Johnson's Executive Committee from March 2005 until his retirement in March 2008. From 2003 to March 2005, Mr. Scodari was Company Group Chairman of Johnson & Johnson's Biopharmaceutical Business. Mr. Scodari joined Johnson & Johnson in 1999 as President and Chief Operating Officer of Centocor Inc., when Johnson & Johnson acquired that company. Mr. Scodari joined Centocor in 1996 as President, Pharmaceutical Division and was named President and COO in 1998. Mr. Scodari began his career in 1974 in sales for Winthrop Laboratories, Division of Sterling Drug. He progressed through various management positions, eventually leading the Diagnostic Imaging Division for Winthrop and later Strategic Marketing at the Corporate level for the Imaging business. Mr. Scodari joined Rorer Pharmaceuticals (shortly thereafter, Rhne-Poulenc Rorer) in 1989 as Vice President of Marketing and Business Development. He later served as Vice President and General Manager for the United States, and subsequently, North America, and finally as Senior Vice President and General Manager for the Americas. Mr. Scodari previously served as a director of Actelion Pharmaceuticals, Ltd., Endo Health Solutions, Inc. and Covance, Inc., and currently serves as a director of Acurx, Inc. (Nasdaq: ACXP), a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration. Mr. Scodari has served on various non-profit boards, including the University of the Health Sciences in Philadelphia, the Board of Overseers for the Robert Wood Johnson School of Medicine, and on the Board of Trustees for Gwynedd Mercy College, and on the Board of Directors for Volunteers in Medicine, Hilton Head, SC. He has also served on various industry association boards, including the NWDA Associate Member Board, the National Pharmaceutical Council, as Vice Chairman of the Biotechnology Industry Organization (BIO), and Chairman of PA BIO. Mr. Scodari received a B.A. from Youngstown State University. - Joseph C. Scodari曾为Johnson & Johnson医药集团全球总裁，一家多元化医疗公司。自2005年3月至2008年3月为"J&J”执行委员。自2003年至2005年3月Scodari先生为J&J生物医药公司集团总裁。Scodari先生于1999年加入J&J公司并自J&J公司收购Centocor公司后，任Centocor董事长及首席营运官。Scodari先生曾为Actelion医药有限公司（医药公司）董事，直至2011年5月。Scodari先生曾任Endo医疗公司董事，该公司自2013年12月发展成为一家多远化医疗健康服务公司。Scodari先生自2008年5月成为Covance公司董事会成员。
- Joseph C. Scodari,has served as Chairman of Optinose, Inc. Board of Directors since October 2017. Mr. Scodari was Worldwide Chairman, Pharmaceuticals Group, of Johnson & Johnson, and a member of Johnson & Johnson's Executive Committee from March 2005 until his retirement in March 2008. From 2003 to March 2005, Mr. Scodari was Company Group Chairman of Johnson & Johnson's Biopharmaceutical Business. Mr. Scodari joined Johnson & Johnson in 1999 as President and Chief Operating Officer of Centocor Inc., when Johnson & Johnson acquired that company. Mr. Scodari joined Centocor in 1996 as President, Pharmaceutical Division and was named President and COO in 1998. Mr. Scodari began his career in 1974 in sales for Winthrop Laboratories, Division of Sterling Drug. He progressed through various management positions, eventually leading the Diagnostic Imaging Division for Winthrop and later Strategic Marketing at the Corporate level for the Imaging business. Mr. Scodari joined Rorer Pharmaceuticals (shortly thereafter, Rhne-Poulenc Rorer) in 1989 as Vice President of Marketing and Business Development. He later served as Vice President and General Manager for the United States, and subsequently, North America, and finally as Senior Vice President and General Manager for the Americas. Mr. Scodari previously served as a director of Actelion Pharmaceuticals, Ltd., Endo Health Solutions, Inc. and Covance, Inc., and currently serves as a director of Acurx, Inc. (Nasdaq: ACXP), a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration. Mr. Scodari has served on various non-profit boards, including the University of the Health Sciences in Philadelphia, the Board of Overseers for the Robert Wood Johnson School of Medicine, and on the Board of Trustees for Gwynedd Mercy College, and on the Board of Directors for Volunteers in Medicine, Hilton Head, SC. He has also served on various industry association boards, including the NWDA Associate Member Board, the National Pharmaceutical Council, as Vice Chairman of the Biotechnology Industry Organization (BIO), and Chairman of PA BIO. Mr. Scodari received a B.A. from Youngstown State University.
高管简历
中英对照 | 中文 | 英文- Ramy A. Mahmoud
RamyA.Mahmoud，M.D.，M.P.H.自2010年以来一直担任我们的总裁兼首席运营官。在加入我们之前，马哈茂德博士在强生公司工作了14年，在那里他担任首席医疗官和Ethicon集团公司全球管理委员会成员。在强生公司任职期间，他还在制药行业担任高级职务。Mahmoud博士在美国陆军（U.S.Army）服役10年，在陆军预备役部队（Army Reserves）再服役10年，达到中校军衔。在服兵役期间，Mahmoud博士担任多个病人护理、研究和学术职位，最终担任Walter Reed Army Institute of Research流行病学系主任。他发表了50多篇同行评议论文和教科书章节，并担任多个期刊和教科书的科学评审员。Mahmoud博士在哈佛大学公共卫生学院获得梦百合管理和政策硕士学位，在迈阿密大学获得医学博士学位。
Ramy A. Mahmoud,has served as Optinose, Inc. Chief Executive Officer and as a member of Optinose, Inc. Board of Directors since January 2023. Prior to being appointed Chief Executive Officer, Dr. Mahmoud served as Optinose, Inc. President and Chief Operating Officer since 2010. Prior to joining Optinose, Inc. , Dr. Mahmoud spent 14 years at Johnson & Johnson, where he most recently served as Chief Medical Officer and a member of the Global Management Board of the Ethicon group of companies. During his tenure at Johnson & Johnson, he also held senior roles in the pharmaceutical sector. Dr. Mahmoud served for 10 years on active duty in the U.S. Army and an additional 10 years in the Army Reserves, achieving the rank of Lieutenant Colonel. During his military service, Dr. Mahmoud held various patient care, research, and academic positions, culminating in his position as the head of the Department of Epidemiology at the Walter Reed Army Institute of Research. He has published more than 80 peer-reviewed papers and textbook chapters, and has served as a scientific reviewer for a number of journals and textbooks. Dr. Mahmoud earned a Master of Healthcare Management and Policy degree from the Harvard School of Public Health and an M.D. from the University of Miami. He has earned board certification in both Public Health/Preventive Medicine and in Internal Medicine.- RamyA.Mahmoud，M.D.，M.P.H.自2010年以来一直担任我们的总裁兼首席运营官。在加入我们之前，马哈茂德博士在强生公司工作了14年，在那里他担任首席医疗官和Ethicon集团公司全球管理委员会成员。在强生公司任职期间，他还在制药行业担任高级职务。Mahmoud博士在美国陆军（U.S.Army）服役10年，在陆军预备役部队（Army Reserves）再服役10年，达到中校军衔。在服兵役期间，Mahmoud博士担任多个病人护理、研究和学术职位，最终担任Walter Reed Army Institute of Research流行病学系主任。他发表了50多篇同行评议论文和教科书章节，并担任多个期刊和教科书的科学评审员。Mahmoud博士在哈佛大学公共卫生学院获得梦百合管理和政策硕士学位，在迈阿密大学获得医学博士学位。
- Ramy A. Mahmoud,has served as Optinose, Inc. Chief Executive Officer and as a member of Optinose, Inc. Board of Directors since January 2023. Prior to being appointed Chief Executive Officer, Dr. Mahmoud served as Optinose, Inc. President and Chief Operating Officer since 2010. Prior to joining Optinose, Inc. , Dr. Mahmoud spent 14 years at Johnson & Johnson, where he most recently served as Chief Medical Officer and a member of the Global Management Board of the Ethicon group of companies. During his tenure at Johnson & Johnson, he also held senior roles in the pharmaceutical sector. Dr. Mahmoud served for 10 years on active duty in the U.S. Army and an additional 10 years in the Army Reserves, achieving the rank of Lieutenant Colonel. During his military service, Dr. Mahmoud held various patient care, research, and academic positions, culminating in his position as the head of the Department of Epidemiology at the Walter Reed Army Institute of Research. He has published more than 80 peer-reviewed papers and textbook chapters, and has served as a scientific reviewer for a number of journals and textbooks. Dr. Mahmoud earned a Master of Healthcare Management and Policy degree from the Harvard School of Public Health and an M.D. from the University of Miami. He has earned board certification in both Public Health/Preventive Medicine and in Internal Medicine.
- Anthony J. Krick
Anthony J. Krick，自2022年6月起担任OptiNose, Inc.首席会计官。在被任命为首席会计官之前，Krick先生自2021年11月起担任OptiNose, Inc.副总裁、财务总监。在加入Optinose之前，Krick先生于2020年2月至2021年11月期间担任上市医疗皮肤病学公司Verrica Pharmaceuticals Inc.的公司控制人。在加入Verrica之前，Krick先生于2017年5月至2020年2月在公开上市的罕见病公司Strongbridge生物制药有限公司担任财务规划与分析执行董事。在其职业生涯的早期，Krick先生曾在葛兰素史克、远藤制药和安永会计师事务所担任过多个责任越来越大的职位。Krick先生获得了奥尔布赖特学院会计学理学学士学位，是一名注册会计师（自愿非活动状态）。
Anthony J. Krick,has served as Optinose, Inc. Chief Accounting Officer since June 2022. Prior to being appointed Chief Accounting Officer, Mr. Krick served as Optinose, Inc. VP, Controller since November 2021. Prior to joining Optinose, Mr. Krick served as the Corporate Controller of Verrica Pharmaceuticals Inc., a publicly-traded medical dermatology company, from February 2020 to November 2021. Prior to joining Verrica, Mr. Krick served as Executive Director, Financial Planning & Analysis at Strongbridge Biopharma, plc, a pubicly-traded rare disease company, from May 2017 to Feburary 2020. Earlier in his career, Mr. Krick held a number of positions of increasing responsibility at GlaxoSmithKline, Endo Pharmaceuticals and Ernst & Young, LLP. Mr. Krick earned a Bachelor of Science in accounting from Albright College and is a Certified Public Accountant (voluntary inactive status).- Anthony J. Krick，自2022年6月起担任OptiNose, Inc.首席会计官。在被任命为首席会计官之前，Krick先生自2021年11月起担任OptiNose, Inc.副总裁、财务总监。在加入Optinose之前，Krick先生于2020年2月至2021年11月期间担任上市医疗皮肤病学公司Verrica Pharmaceuticals Inc.的公司控制人。在加入Verrica之前，Krick先生于2017年5月至2020年2月在公开上市的罕见病公司Strongbridge生物制药有限公司担任财务规划与分析执行董事。在其职业生涯的早期，Krick先生曾在葛兰素史克、远藤制药和安永会计师事务所担任过多个责任越来越大的职位。Krick先生获得了奥尔布赖特学院会计学理学学士学位，是一名注册会计师（自愿非活动状态）。
- Anthony J. Krick,has served as Optinose, Inc. Chief Accounting Officer since June 2022. Prior to being appointed Chief Accounting Officer, Mr. Krick served as Optinose, Inc. VP, Controller since November 2021. Prior to joining Optinose, Mr. Krick served as the Corporate Controller of Verrica Pharmaceuticals Inc., a publicly-traded medical dermatology company, from February 2020 to November 2021. Prior to joining Verrica, Mr. Krick served as Executive Director, Financial Planning & Analysis at Strongbridge Biopharma, plc, a pubicly-traded rare disease company, from May 2017 to Feburary 2020. Earlier in his career, Mr. Krick held a number of positions of increasing responsibility at GlaxoSmithKline, Endo Pharmaceuticals and Ernst & Young, LLP. Mr. Krick earned a Bachelor of Science in accounting from Albright College and is a Certified Public Accountant (voluntary inactive status).
- Paul Spence
Paul Spence，自2022年12月起担任OptiNose, Inc.首席商务官。在加入Optinose之前，Spence先生最近担任雀巢Health Sciences高级副总裁兼美国制药首席商务官，在2020年至2022年期间领导Aimmune胃肠和食物过敏业务，在此之前，2016年至2019年担任雀巢Health Sciences美国商业副总裁。在加入雀巢Health Sciences之前，他在勃林格殷格翰制药、赛诺菲安万特和百时美施贵宝担任的商业职务责任越来越大。Spence先生在宾夕法尼亚州立大学获得金融和会计理学学士学位，并在维拉诺瓦大学获得MBA学位。
Paul Spence,has served as Optinose, Inc. Chief Commercial Officer since December 2022. Prior to joining Optinose, Mr. Spence was most recently the Senior Vice President and U.S. Pharma Chief Commercial Officer at Nestlé Health Sciences where he led the Aimmune Gastrointestinal and Food Allergy businesses from 2020 to 2022 and prior to that, VP U.S. Commercial at Nestlé Health Sciences from 2016 to 2019. Prior to joining Nestlé Health Sciences, he had commercial roles of increasing responsibility at Boehringer-Ingelheim Pharmaceuticals, Sanofi-Aventis, and Bristol-Myers Squibb. Mr. Spence earned a Bachelor of Science in Finance and Accounting from Penn State University and an MBA from Villanova University.- Paul Spence，自2022年12月起担任OptiNose, Inc.首席商务官。在加入Optinose之前，Spence先生最近担任雀巢Health Sciences高级副总裁兼美国制药首席商务官，在2020年至2022年期间领导Aimmune胃肠和食物过敏业务，在此之前，2016年至2019年担任雀巢Health Sciences美国商业副总裁。在加入雀巢Health Sciences之前，他在勃林格殷格翰制药、赛诺菲安万特和百时美施贵宝担任的商业职务责任越来越大。Spence先生在宾夕法尼亚州立大学获得金融和会计理学学士学位，并在维拉诺瓦大学获得MBA学位。
- Paul Spence,has served as Optinose, Inc. Chief Commercial Officer since December 2022. Prior to joining Optinose, Mr. Spence was most recently the Senior Vice President and U.S. Pharma Chief Commercial Officer at Nestlé Health Sciences where he led the Aimmune Gastrointestinal and Food Allergy businesses from 2020 to 2022 and prior to that, VP U.S. Commercial at Nestlé Health Sciences from 2016 to 2019. Prior to joining Nestlé Health Sciences, he had commercial roles of increasing responsibility at Boehringer-Ingelheim Pharmaceuticals, Sanofi-Aventis, and Bristol-Myers Squibb. Mr. Spence earned a Bachelor of Science in Finance and Accounting from Penn State University and an MBA from Villanova University.
- Michael F. Marino
Michael F. Marino， Marino先生，2010年10月以来一直是Optinose, Inc.的副总裁，总顾问和秘书。加入NuPathe之前，从2005年3月至2010年10月，Marino先生在Morgan, Lewis & Bockius LLP任职，从2001年10月至2005年3月，在WilmerHale LLP律师事务所任职。在Morgan, Lewis & Bockius 和 WilmerHale时，Marino先生的实践主要集中在为生命科学技术和其他公司提供广泛问题建议，包括并购、证券、金融、公司治理、遵从性和其他一般公司事务。Marino先生拥有Villanova University会计学士学位和波士顿大学法学院法学博士学位。
Michael F. Marino,has served as Optinose, Inc. Chief Legal Officer and Corporate Secretary since January 2017 and as a member of the board of directors of OptiNose AS since June 2018. Prior to joining Optinose, Mr. Marino served as Senior Vice President, General Counsel and Corporate Secretary of Fibrocell Science, Inc., a publicly-traded cell and gene therapy company, from 2015 to 2017, and as Senior Vice President, General Counsel and Corporate Secretary of NuPathe Inc., a publicly-traded specialty pharmaceutical company from 2010 until the sale of NuPathe to Teva Pharmaceutical Industries Ltd. in 2014. From 2001 to 2010, Mr. Marino was an attorney at the law firms of Morgan, Lewis & Bockius LLP and WilmerHale LLP where his practice focused on mergers and acquisitions, financing transactions, collaborations, corporate governance, securities and other general corporate matters. Mr. Marino earned a B.S. in Accountancy from Villanova University and a J.D. from Boston College Law School.- Michael F. Marino， Marino先生，2010年10月以来一直是Optinose, Inc.的副总裁，总顾问和秘书。加入NuPathe之前，从2005年3月至2010年10月，Marino先生在Morgan, Lewis & Bockius LLP任职，从2001年10月至2005年3月，在WilmerHale LLP律师事务所任职。在Morgan, Lewis & Bockius 和 WilmerHale时，Marino先生的实践主要集中在为生命科学技术和其他公司提供广泛问题建议，包括并购、证券、金融、公司治理、遵从性和其他一般公司事务。Marino先生拥有Villanova University会计学士学位和波士顿大学法学院法学博士学位。
- Michael F. Marino,has served as Optinose, Inc. Chief Legal Officer and Corporate Secretary since January 2017 and as a member of the board of directors of OptiNose AS since June 2018. Prior to joining Optinose, Mr. Marino served as Senior Vice President, General Counsel and Corporate Secretary of Fibrocell Science, Inc., a publicly-traded cell and gene therapy company, from 2015 to 2017, and as Senior Vice President, General Counsel and Corporate Secretary of NuPathe Inc., a publicly-traded specialty pharmaceutical company from 2010 until the sale of NuPathe to Teva Pharmaceutical Industries Ltd. in 2014. From 2001 to 2010, Mr. Marino was an attorney at the law firms of Morgan, Lewis & Bockius LLP and WilmerHale LLP where his practice focused on mergers and acquisitions, financing transactions, collaborations, corporate governance, securities and other general corporate matters. Mr. Marino earned a B.S. in Accountancy from Villanova University and a J.D. from Boston College Law School.